Skip to Main Content

Paper Details

Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity.
Immunity
129
2021
IFN-I, SARS, SARS-CoV, SARS-CoV-2, recombinant IFN-I, severe acute respiratory syndrome coronavirus, type I interferon, viral disease
Author NameAffiliation
David SachsIcahn School of Medicine at Mount Sinai
David SachsIcahn School of Medicine at Mount Sinai
Jean K LimIcahn School of Medicine at Mount Sinai
Benjamin R tenOeverIcahn School of Medicine at Mount Sinai
  • 1 - 4

Datasets

Release 1.2